IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign

Rhea-AI Summary

Market Context

IGC's recent news record contained 2 aligned and 3 divergent reactions, adding a mixed historical fr...

Analysis

IGC's recent news record contained 2 aligned and 3 divergent reactions, adding a mixed historical frame to this remedies evaluation. The active resale registration covers 978,235 shares and provides no company proceeds, a relevant structural risk.

Key Figures

Guilty counts: 1 count and 12 counts Short campaign date: October 2018 Hedge fund profits: more than $3.8 million +4 more

7 metrics

Guilty counts 1 count and 12 counts Federal jury verdict against Andrew Left

Short campaign date October 2018 Alleged campaign targeting IGC

Hedge fund profits more than $3.8 million Alleged profits from trading related to short campaigns

Left profits more than $1.1 million Alleged profits from trading related to short campaigns

AIMF trading profits $500,000 Trading profits from AIMF short positions on the IGC tweet date

Civil penalties $2.25 million Combined penalties agreed to by Anson entities

Trial phase Phase 2 CALMA trial evaluating IGC-AD1

Historical Context

5 past events · Latest: Jul 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 09	AI showcase	Positive	+1.4%	Company planned seven AAIC presentations featuring its Alzheimer's-focused AI portfolio.
Jul 07	Insider stock purchase	Positive	-1.1%	Executives acquired common shares by converting company obligations into equity.
Jun 23	AI platform launch	Positive	-0.6%	AHA beta launch reported a major reduction in Alzheimer's data harmonization time.
Jun 11	Phase 2 enrollment	Positive	+0.5%	CALMA reached its planned enrollment target and advanced toward topline analysis.
Jun 09	Price target increase	Positive	-4.7%	Ascendiant Capital Markets raised its price target citing clinical progress and catalysts.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

IGC's recent positive announcements produced mixed outcomes, with two aligned reactions and three divergences.

Key Terms

securities fraud, short campaign, short positions, phase 2

4 terms

securities fraud regulatory

"was found guilty of one count of engaging in a securities fraud scheme"

Securities fraud is the illegal act of lying to or misleading investors about the true value or prospects of stocks, bonds or other traded financial instruments — for example by making false statements, hiding key facts, trading on secret information, or artificially moving prices. It matters to investors because it can cause sudden losses, distort fair market prices and undermine trust in markets; think of it as someone rigging a scoreboard so others place bets on the wrong team.

View in glossary

short campaign financial

"execute a short campaign targeting IGC"

A short campaign is a coordinated effort by investors or research groups to profit from a drop in a company's share price by taking short positions and often publicizing negative analysis, allegations, or data about the company. It matters to investors because these campaigns can shift market sentiment, drive selling, increase price volatility and trading volume, and create short-term moves in a stock that may be separate from the company's underlying business performance.

short positions financial

"AIMF's short positions on the day of the IGC tweet"

Short positions are bets that a stock’s price will fall, created when an investor borrows shares and sells them now with the plan to buy them back later at a lower price and return them. They matter to investors because large or concentrated short positions can pressure a stock’s price, increase volatility, and signal market skepticism about a company’s prospects—like someone publicly betting against a team, which can affect other bettors’ actions.

phase 2 medical

"including the Phase 2 CALMA clinical trial"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

POTOMAC, MD / ACCESS Newswire / July 29, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that it is evaluating potential civil remedies following the federal jury verdict in United States v. Andrew Left, No. 2:24-CR-456, in the United States District Court for the Central District of California.

According to the United States Attorney's Office for the Central District of California, Andrew Left, founder of Citron Research, was found guilty of one count of engaging in a securities fraud scheme and 12 counts of securities fraud. The verdict follows a federal indictment that identified IGC, then known as India Globalization Capital, Inc., as one of the companies targeted in the alleged scheme.

IGC is evaluating whether the public record supports potential claims to recover damages arising from the alleged short campaign and related conduct that affected the Company and its shareholders.

The indictment alleged that, in October 2018, Left and a hedge fund worked together to execute a short campaign targeting IGC. The Company believes the public record raises serious questions regarding the conduct surrounding that campaign and its impact on IGC and its shareholders.

"The public record now describes conduct that we believe warrants serious review," said Ram Mukunda, Chief Executive Officer of IGC Pharma. "Our shareholders have asked for years what happened during the 2018 short campaign. We are now evaluating whether IGC has recoverable damages and what remedies may be available to protect the interests of the Company and its shareholders."

IGC is reviewing the federal indictment, the jury verdict, and related SEC materials, and is evaluating potential civil remedies. The Company is also evaluating whether recoverable damages may include harm to market value, reputational and operational harm, and legal and regulatory costs incurred in connection with matters arising from the conduct described in the public record. Any decision to pursue claims will be made by the Board of Directors, based on the recommendation of counsel and in the best interests of the Company and its shareholders.

The public record also describes financial incentives associated with the alleged short campaigns. The indictment alleged that trading related to short campaigns targeting IGC and another issuer generated more than $3.8 million in profits for the hedge fund involved and more than $1.1 million in profits for Left.

In a separate settled administrative proceeding, the Securities and Exchange Commission order stated that Anson Advisors agreed to pay a short publisher a share of trading profits from trading around a bearish tweet concerning IGC. According to the SEC order, AIMF's short positions on the day of the IGC tweet generated approximately $500,000 in trading profits. Without admitting or denying the SEC's findings, Anson Funds Management LP and Anson Advisors Inc. agreed to pay combined civil monetary penalties of $2.25 million.

The Company's primary operational focus remains the advancement of its Alzheimer's disease programs, including the Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation associated with Alzheimer's disease.

About IGC Pharma, Inc. (dba IGC, NYSE American: IGC):

IGC Pharma is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. The Company's lead asset, IGC-AD1, is currently being evaluated in a Phase 2 CALMA trial for agitation associated with Alzheimer's dementia. The Company's pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, sleep, and metabolic dysfunctions. IGC integrates AI to support drug discovery, clinical trials optimization, and patient targeting.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's evaluation of potential civil remedies, potential claims, recoverable damages, Board and counsel review, and the Company's Alzheimer's disease programs, including IGC-AD1 and the CALMA trial. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially, including risks related to the availability and viability of any claims, the amount and recoverability of any damages, the timing, cost, and outcome of any potential proceedings, decisions by the Board of Directors and counsel, the Company's ability to complete enrollment in its Phase 2 CALMA trial within anticipated timeframes, demonstrate safety and efficacy, the timing of data readouts, regulatory approvals, and other factors discussed in the Company's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-KT. The Company undertakes no obligation to update these statements except as required by law.

Contact Information:
Andres Sanchez
Investor Relations
info@igcpharma.com
+1 301-983-0998 / +1 (202) 569-2566

SOURCE: IGC Pharma, Inc.

View the original press release on ACCESS Newswire